Back to top
more

CRISPR Therapeutics (CRSP)

(Delayed Data from NSDQ)

$53.10 USD

53.10
1,072,367

-0.80 (-1.48%)

Updated Jul 5, 2024 04:00 PM ET

After-Market: $53.09 -0.01 (-0.02%) 7:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 249)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Is CRISPR THERAPTC (CRSP) Outperforming Other Medical Stocks This Year?

Is (CRSP) Outperforming Other Medical Stocks This Year?

CRISPR THERAPTC (CRSP) Reports Q3 Loss, Misses Revenue Estimates

CRISPR THERAPTC (CRSP) delivered earnings and revenue surprises of -44.59% and -83.91%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Cronos (CRON) to Report Q3 Earnings: What's in the Cards?

Investors will focus on pipeline progress and updates when Cronos (CRON) reports third-quarter results.

CRISPR THERAPTC (CRSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

CRISPR THERAPTC (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in the Cards for Perrigo (PRGO) This Earnings Season?

Perrigo (PRGO) focuses on growth strategy for Consumer Healthcare Americas segment. The company plans to divest its loss-making Rx segment.

What Lies in Store for Ligand (LGND) This Earnings Season?

Ligand's (LGND) partnered programs - Kyprolis and Promacta - using its Captisol formulation technology are expected to drive milestone and royalty payments in third-quarter 2018.

Is A Disappointment in Store for Tilray (TLRY) Q3 Earnings?

Investors will focus on pipeline progress and updates when Tilray (TLRY) reports third-quarter results.

Endo (ENDP) to Report Q3 Earnings: What's in the Cards?

Investors are expected to focus on the Xiaflex performance and pipeline updates when Endo (ENDP) reports third-quarter results.

Is a Beat in Store for Humana (HUM) Stock in Q3 Earnings?

Humana's (HUM) Q3 is likely to gain from solid segmental performances and higher enrollment.

ImmunoGen (IMGN) Beats on Earnings in Q3, Lowers Guidance

ImmunoGen (IMGN) reports narrower-than-expected loss in Q3. However, it misses estimates for revenues. Shares down.

What's in the Cards for Nektar (NKTR) This Earnings Season?

Nektar Therapeutics (NKTR) will report third-quarter results on Nov 7. Investors are expected to focus on pipeline progress.

5 Drug/Biotech Stocks Set to Trump Estimates in Q3 Earnings

There are still a number of drug/biotech companies poised to surpass third-quarter estimates.

VIVUS (VVUS) Q3 Loss Narrower Than Expected, Revenues Up Y/Y

VIVUS (VVUS) reports narrower-than-expected loss in the third quarter. Sales increase year over year.

Geron's (GERN) Q3 Earnings Beat, Revenues Miss, Shares Down

Geron (GERN) beats earnings estimates in the third quarter but misses on revenues. Operating expenses decrease year over year.

Ophthotech (OPHT) Q3 Earnings Beat, Gene Therapy in Focus

Ophthotech reports narrower-than-expected loss in the third quarter. It boosts gene therapy pipeline through new agreement and acquisition.

Match Group (MTCH) to Report Q3 Earnings: Is a Beat in Store?

Match Group (MTCH) boasts of a robust product portfolio comprising Tinder, Match.com, Meetic, PlentyOfFish and OkCupid.

Is a Beat in Store for Editas (EDIT) This Earnings Season?

On Editas' (EDIT) third-quarter conference call, investor focus will be on the company's progress with its proprietary genome editing platform based on CRISPR technology.

What's in Store for Verastem (VSTM) This Earnings Season?

On Verastem's (VSTM) third-quarter conference call, investor focus will be on the company's launch and reimbursement plans for its newly approved leukemia drug Copiktra.

Is a Beat in Store for CRISPR (CRSP) This Earnings Season?

We expect CRISPR (CRSP) to provide updates on its pipeline candidates in the third quarter of 2018.

Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q2

Dr. Reddy's (RDY) surpasses earnings and revenue estimates on strength across segments in the second quarter of fiscal 2019.

What's in Store for Sangamo (SGMO) This Earnings Season?

On Sangamo's (SGMO) Q3 2018 conference call, investor focus will be on the company's progress with its genome editing and gene regulation technology platform.

Vertex (VRTX) Q3 Earnings and Revenues Surpass Estimates

Vertex' (VRTX) Q3 gains on earnings and revenue beat with demand for its CF products rising high.

Alexion's (ALXN) Earnings Beat Estimates in Q3, Guidance Up

Alexion (ALXN) beats earnings estimates and marginally misses sales estimates in the third quarter of 2018. The company also inks a deal to acquire Syntimmune for $1.2 billion.

Is a Beat in Store for Vertex (VRTX) This Earnings Season?

On Vertex' (VRTX) third-quarter 2018 earnings call, investor focus will be on the sales figures of its newest CF drug, Symdeko.

Company News For Oct 12, 2018

Companies in the news are: DAL, WBA, COST and CRSP